logo-loader
HealthPharma & Biotech
viewTissue Regenix Group PLC

Tissue Regenix chief: Commercialisation now key

Antony Odell, chief executive of Tissue Regenix (LON:TRX), discusses the company’s commercialisation push for its advanced wound care product.

Today, the AIM-listed group revealed it will be sharing the latest data on DermaPure with some of the industry’s leading professionals at the Symposium for Advanced Wound Care’s spring meeting in the US.

It follows the news of a ‘critical step’ towards regulatory sign-off for the start of clinical trials for Orthopure XT, a decellularised tendon device for the reconstruction of a torn anterior cruciate ligament – a career-threatening injury for footballers and other athletes.

Quick facts: Tissue Regenix Group PLC

Price: 2.75 GBX

AIM:TRX
Market: AIM
Market Cap: £32.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Holding(s) in Company

3 days, 10 hours ago

Trading Update

3 days, 19 hours ago

Holding(s) in Company

5 days, 11 hours ago

Appointment of CFO

on 08/28/2019

Directorate Change

on 08/01/2019

2 min read